It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

A Maryland jury has convicted both former CytoDyn CEO Nader Pourhassan, Ph.D., and ex-Amarex CEO Kazem Kazempour on several ...

Danish pharma company Bavarian Nordic is shutting down its U.S.-based R&D site in San Diego and laying off all 48 employees ...

A phase 3 prostate cancer trial of Candel’s oncolytic virus has met its primary endpoint, sending the stock up more than 200% ...

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...

Capstan Medical has reeled in $110 million to continue its mission of bringing robotic surgery to a previously untouched ...

Two Boston-area biotechs are shedding staff and merging together to form a new genetic medicines company. | Chroma Medicines ...

The U.S. Preventive Services Task Force pitched an update to its guidelines for cervical cancer screening, endorsing HPV ...

Cellectar Biosciences is laying off 60% of its employees and halting work on its sole clinical-stage radiotherapy after the ...

Hepion Pharmaceuticals and Pharma Two B have terminated a reverse merger agreement that was expected to close by the end of ...

Less than a year after completing a series B extension round, Angitia Biopharmaceuticals has set its sights even higher with ...